Start with the job, not the tool
Most complaints about AI stock analysis tools are really category errors. Someone buys a sentiment tracker expecting a research report, or a screener expecting a recommendation, and concludes the technology doesn't work. The technology worked; it just wasn't doing the job they had in mind.
Four categories, in rough order of how much interpretation they do for you.
1. Screeners and rankers
Filter a universe of thousands down to a shortlist using rules — valuation bands, growth thresholds, momentum, quality scores. The "AI" is usually a weighting model that combines factors into a single rank.
Good for: narrowing. If you don't know where to start, this is where you start.
Not good for: telling you why. A rank is an output with no argument attached, and a rank derived from a proprietary weighting you can't inspect is a number you have to take on faith. Screeners are also prone to look brilliant in backtests and ordinary in practice, because the weights were chosen with the historical data already visible.
2. Sentiment trackers
Score news, filings language, and sometimes social chatter into a directional signal.
Good for: noticing that the tone around a company has shifted before you'd have caught it manually. Genuinely useful as an alerting layer.
Not good for: anything on its own. Sentiment measures coverage, not fundamentals, and coverage is a reaction to price at least as often as a cause of it. News sentiment is also highly sensitive to which articles the tool happened to ingest, which is rarely disclosed.
3. Chat assistants over documents
Ask questions about a company and get answers drawn from filings and transcripts.
Good for: targeted retrieval. "What did management say about margins on the last call?" is exactly the question this format answers well, and it answers it in seconds.
Not good for: questions you didn't know to ask. A chat interface only surfaces what you probe for, so it inherits your blind spots. This is also the category most exposed to fluent fabrication — if the retrieval misses, a language model will often answer from memory rather than decline, and the answer will read exactly like the correct one.
4. Research tools that produce a written analysis
Synthesize the available evidence into a document with a conclusion, the reasoning behind it, and ideally the conditions that would overturn it.
Good for: the case where you want a starting position you can argue with rather than a data dump.
Not good for: speed, or people who want a number. These produce prose, and prose takes longer to read than a score.
This is the category Synoptiv is in, and it's worth saying plainly: if what you want is a one-glance ranking, a screener will serve you better.
The seven questions
These apply regardless of category, and they're the ones that actually separate a research tool from a confident-sounding wrapper. Accuracy claims are close to unfalsifiable — over what horizon, against what benchmark, on which universe, with how many quiet revisions — so ask these instead.
1. Does it show its evidence? Every material claim should trace to a source you can open. "Revenue growth is decelerating" is an assertion. "Revenue growth fell from 24% to 11% year over year across three quarters (Q3 FY26 10-Q)" is checkable. If you can't get from a claim to a document, you're being asked to trust rather than verify.
2. Is it dated? Market analysis has a shelf life of weeks. An undated analysis isn't analysis, it's a document. This one takes two seconds to check and eliminates a surprising number of tools.
3. Are the numbers computed or generated? The single most diagnostic question. In a serious tool, financial metrics are calculated deterministically from source data and the model only writes the prose around them. In a wrapper, the model produces the numbers too — which is why they're occasionally plausible and wrong. Ask directly; a vendor doing the harder thing will be happy to explain it.
4. Does it ever say the evidence is mixed? A tool that reaches a clean verdict on every company isn't analyzing them. Real evidence is frequently ambiguous, and a system that never reports ambiguity has been designed to produce confidence rather than findings. The honest output for a genuinely unclear setup is no trade.
5. Does it state what would change its mind? A conclusion without invalidation conditions can't be monitored. It's the difference between an opinion and a thesis — and it's what lets you hold the tool accountable later. (What should make you sell covers how to write these properly.)
6. Does it version its analyses? Situations change. A tool that overwrites its previous view and leaves no record is one you can't audit and can't learn from. Versioned analyses and an honest track record are what make a claim of usefulness checkable rather than asserted.
7. How does it present past performance? Watch for survivorship-flattered backtests and results fitted to data the model already saw. Any hypothetical performance figure should be labeled as hypothetical, with its assumptions stated. Real-world results are what matter, and honest tools are noticeably more cautious here than marketing pages are.
Where Synoptiv fits, and where it doesn't
Since this is published by Synoptiv, the useful thing is to be specific rather than flattering.
What it is: a research tool in category 4. For each covered US stock it produces a versioned analysis — a verdict, the reasoning, and the conditions that would invalidate it — synthesizing financials, filings, insider and congressional activity, fund exposure, sentiment, and macro context. Public stock overviews, comparisons, and the glossary are browsable without an account. It's currently free while in trial; there are no paid plans at the time of writing.
What it isn't:
- Not a screener. Coverage is roughly 106 symbols, not the whole market. If you want to filter 5,000 tickers, this is the wrong tool.
- Not real-time. Analyses are versioned as the story changes, not streamed. Day traders are not the audience.
- Not a prediction engine. It won't tell you where a price is going, because nothing reliably can.
- Not advice. It's research. The decision stays with you.
The honest summary of the whole category: use these tools to do the reading, not the deciding. Delegating the reading is a clear gain — no individual investor has time to work through a 10-K, four transcripts, and a quarter of filings for thirty companies. Delegating the conviction reproduces the original problem in a new form: acting on a conclusion you can't interrogate, now arriving in confident, well-formatted prose.
For the longer argument about what AI can and can't do here, see can AI analyze stocks.